Autumn 2026
Special: CROs & CDMOs
CDMOs and CROs need to integrate new clinical trial designs, innovative drug modalities, and AI into their service portfolios. At the same time, they are facing a shortage of qualified personnel.
Drug developers rely on CROs and CDMOs for more than extra capacity. Their partners help shape clinical trials, transfer manufacturing processes and scale up increasingly complex medicines. But every handover raises a question: Who is responsible when something goes wrong?
In this special edition of European Biotechnology, we examine how Europe’s outsourcing model is changing. Should a biotech work with one partner from development through manufacturing, or bring together specialists at each stage? We look at what makes technology transfer work, why European CDMOs are expanding in the U.S. and how demand for antibody-drug conjugates is driving investment in new manufacturing capabilities.
We also speak with WuXi AppTec about its expansion in Europe and examine why running clinical trials across multiple European countries is creating more demand for CRO support.
This special is part of the Autumn issue of our magazine.
